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Abstract
Background: The goal of this study was to investigate ERBB2(HER2) and EGFR gene amplification and protein
expression in gastric cancer. Fluorescence in situ hybridization (FISH) and immunohistochemistry were used to
analyze ERBB2 and EGFR gene amplification and protein expression in 69 cases of gastric cancer.
Results: FISH analysis revealed that 20.3% of the cases exhibited ERBB2 gene amplification. Increases in ERBB2 copy
number and gene amplification were present in 52.2% of the samples. Expression of the ERBB2 protein was
observed in 42.0% of cases. FISH analysis detected EGFR gene amplification in 29.0% of samples. Increases in EGFR
copy number and gene amplification occurred in 57.9% of samples, and EGFR protein expression was present in
52.2% of samples. Both ERBB2 and EGFR gene amplification were 3 cases (4.3%), but abnormalities in both ERBB2
and EGFR gene copy number were present 36.2% of samples. ERBB2 and EGFR gene amplification were significantly
associated with the depth of tumor invasion (P < 0.05) and lymph node metastasis (P < 0.05), but not with sex,
age, or histological type (P > 0.05).
Conclusions: Our data indicated that ERBB2 and EGFR genetic abnormalities were associated with the prognosis of
gastric cancer. Clinical assessment of ERBB2 and EGFR amplification may represent an important factor for the
development of personalized treatment programs for gastic cancer.
Introduction
Overexpression of the human epidermal growth factor
receptor 2 (ERBB2(HER2)), also known as C-erbB-2, can
lead to the activation of cellular signal transduction sys-
tems, resulting in the cellular transformation and cell
proliferation events associated with cancer [1]. ERBB2 is
very similar in structure to the epidermal growth factor
receptor (EGFR), with approximately 95% homology
between the 260 amino acid intracellular region (aa 727-
986), which contains the EGFR tyrosine kinase domain,
and the corresponding domain in EGFR.B o t hERBB2
and EGFR are membrane-associated tyrosine kinases
and contain three functional domains: the extracellular
ligand binding domain (aa 1-632), a lipophilic
transmembrane segment (aa 633-654), and a cytoplas-
mic domain that exhibits tyrosine kinase activity (aa
655-1234) [2,3], ERBB2 is frequently unregulated in
human cancers such as breast cancer [4], ovarian cancer
[5], and so on. High expression level of ERBB2 has been
significantly correlated with increased tumor invasion,
metastasis, resistance to chemotherapy, and poor prog-
nosis of patients [6]. However, a lack of reliable and
accurate methods to assess the relationship between
EGFR and ERBB2 gene status and protein expression in
gastric cancer has limited correlative assessments with
clinical parameters, including survival and sensitivity to
targeted agents. Therefore, in the present study, we uti-
lized fluorescence in situ hybridization (FISH) to assess
amplification of the ERBB2 and EGFR genes in gastric
cancer patient samples. We combined this data with
results from histopathological and immunohistochemical
analyses to determine the relationship between ERBB2
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ables in gastric cancer.
Materials and methods
Patients and tumor samples
A total of 69 gastric cancer patients who underwent
radical gastrectomy at the Liberation Army No. 150
Central Hospital between July, 2008 and March, 2010
were included in this study. Tumor subtypes included
16 papillary adenocarcinomas, 14 tubular gland cancers,
15 mucinous adenocarcinomas, 13 poorly differentiated
adenocarcinomas, and 11 signet ring cell carcinomas.
T h ea v e r a g ea g eo ft h ep a t i e n t sa tt h et i m eo fs u r g e r y
was 59.2 years (range, 31-76 years). Tumor specimens
were collected after obtaining informed consent from
the patients in accordance with institutional guidelines.
The samples were fixed in 10% neutral formalin in pre-
paration for further studies.
FISH analysis
ERBB2 and EGFR gene amplification were analyzed by
FISH using the Vysis Path Vysion ERBB2/DNA probe
kit and the LSI EGFR SpectrumOrange/CEP 7 Spec-
trumGreen probe, respectively, according to manufac-
turer’s instructions (Abbott Molecular, Abbott Park, IL,
USA). Briefly, samples fixed in 10% formalin and
embedded in paraffin were cut into 4 μms e c t i o n sa n d
incubated overnight at 56 °C. Slides were dewaxed in
xylene and dehydrated in 100% alcohol for 5 min, fol-
lowed by air drying. The slides were then incubated in
proteinase K solution (0.2 mg/mL in 2 × SSC) at 37 °C
for 15 min, washed with 2 × SSC (pH 7.0), and sequen-
tially dehydrated in 70%, 85%, and 100% ethanol. After
the application of 10 μl of probe to the target area of
the slide, a coverslip was placed over the sample and
sealed. Following denaturation at 73 °C for 5 min, the
slides were allowed to hybridize overnight at 37 °C in a
humidified chamber. After hybridization, the slides were
washed in 0.4 × SSC containing 0.3% Nonidet P40 at 65
°C for 2 min and rinsed twice in 2 × SSC containing
0.1% Nonidet P40 for 2 min. The slides were then
immersed in 70% ethanol for 3 min and dried at room
temperature. After the slides were counterstained with
4’, 6-Diamidino-2-phenylindole dihydrochloride (DAPI),
they were observed under a fluorescence microscope
(Carl Zeiss, Goettingen, Germany)[7].
ERBB2 levels were reported as ERBB2 gene: CEP 17
ratios in order to normalize values to the total number
of chromosomes within each cell. Amplification was
defined as an ERBB2 gene/CEP 17 ratios greater than or
equal to 2.0 [8]. EGFR gene amplification was defined
based on the criteria suggested by M Varella-Garcia, et
al [9]. Several FISH patterns were identified for EGFR:
(1)EGFR FISH-positive: (a) at least 15 copies of the
EGFR signals in ≥ 10% of tumour cells (b) Specimens
that have ≥ 40% of cells displaying ≥ 4c o p i e so ft h e
EGFR signal.(c) EGFR/CEP7 ratio ~ 1, but the presence
of gene cluster (≥ 4 spots) in ≥ 10% of tumour cells;(d)
EGFR/CEP7 ratio ≥ 2 and the presence of gene cluster
(≥ 4s p o t s )i n≥ 10% of tumour cells;(2) EGFR FISH-
negative: Specimens that do not display gene amplifica-
tion according to the criteria defined above and with
<40% of cells displaying ≥ 4 copies of the EGFR signal.
Immunohistochemistry
ERBB2 and EGFR protein expression were evaluated by
immunohistochemistry using the HercepTest™ and
EGFR pharmDx™ kits, respectively, according to the
manufacturer’s recommended protocols (DAKO, Car-
pinteria, CA, USA). Two pathologists independently
scored slides as 0, 1
+,2
+,o r3
+ according to the guide-
lines provided by DAKO. As defined in the manufac-
turer’s instructions, scores of 0 or 1
+ were considered
negative, a score of 2
+ was weakly positive, and a score
of 3
+ was strongly positive.
Statistical analysis
The SPSS 13.0 statistical package (SPSS, Inc., Chicago,
IL, USA) was used for all statistical analyses. A c
2 test
was used for comparisons with ERBB2 and EGFR gene
amplification. P-values less than 0.05 were considered to
be statistically significant.
Results
ERBB2 gene amplification and protein expression
Of the 69 gastric tumors, 14 (20.3%) cases exhibited
ERBB2 gene amplification (Figure 1A). Of the remaining
55 cases without ERBB2 gene amplification, the copy
number was increased in 22 cases. Therefore, ERBB2
copy number increases or gene amplification were
observed in a total of 52.2% (36/69) of the samples. The
ERBB2 protein was expressed (Figure 1B) in 42.0% (29/
69) of the samples. Overexpression of the ERBB2 pro-
tein, evident as immunostaining scores of 2
+ or 3
+,w a s
frequently associated with ERBB2 gene amplification, as
ERBB2 gene amplification was present in 7 of 9 tumors
with a score of 2
+ and in 4 of 4 tumors with a score of
3
+. Tumors that exhibited a staining score of 1
+ were
classified as having a low amplification rate, as only 3 of
16 samples exhibited ERBB2 amplification. Samples with
scores of 1
+ exhibited a significant difference in levels of
ERBB2 amplification in comparison to samples with
scores of 2
+ and 3
+ (P < 0.05, Table 1).
EGFR gene amplification and protein expression
Of the 69 patient samples, 29.0% (20/69) exhibited
EGFR gene amplification (Figure 1C). Interestingly, over-
expression of the EGFR protein in the absence of EGFR
YK et al. Molecular Cytogenetics 2011, 4:14
http://www.molecularcytogenetics.org/content/4/1/14
Page 2 of 6gene amplification was observed more frequently than
expected. A total of 40/69 cases exhibited increases in
EGFR gene copy number in the all samples. The EGFR
protein was expressed in 52.2% (36/69) of patient sam-
ples (Figure 1D). Immunohistochemical analysis revealed
that samples with EGFR protein expression scores of 3
+
and 2
+ exhibited significantly higher levels of gene
amplification than those with scores of 1
+ (5/5 and 10/
11 vs. 5/20, respectively; P < 0.05; Table 2).
Relationship between ERBB2 and EGFR gene
abnormalities in gastric cancer
ERBB2 copy number alterations and gene amplification
occurred in a total of 52.2% (36/69) of patient samples.
EGFR copy number alterations and gene amplification
occurred in a total of 57.9% (40/69) of patient samples.
Both ERBB2 and EGFR gene amplification were 3 cases
(4.3%), but abnormalities in both ERBB2 and EGFR gene
copy number were present 36.2% of samples, indicating
that abnormalities in the two genes may be correlated.
Correlation between ERBB2 and EGFR gene amplification
and clinicopatholigical parameters in gastric cancer
ERBB2 and EGFR gene amplification were not asso-
ciated with sex, age, or histological type (P > 0.05) in
             F i g u r e 1 . ( A )                                            F i g u r e 1   . ( B )  
                F i gure1.(C)                                      F i gure1.(D) 
Figure 1 ERBB2 and EGFR gene amplification and protein expression in gastric cancer samples. (A) Representative image showing ERBB2
gene amplification in a gastric adenocarcinoma sample analyzed by FISH. The ratio of red to green signal is greater than 2, indicative of ERBB2
gene amplification (magnification, 1000 ×). (B) Representative image showing ERBB2 protein expression analyzed by IHC in a poorly-differentiated
gastric adenocarcinoma (IHC score, 3
+; magnification, 200 ×). (C) Representative image showing EGFR gene amplification in a gastric
adenocarcinoma sample analyzed by FISH. The green signal corresponds to chromosome 7, and the red signal corresponds to EGFR. EGFR gene
amplification is visible as red clustering (magnification, 1000 ×). (D) Representative image showing EGFR protein expression analyzed by IHC in a
poorly-differentiated gastric adenocarcinoma (IHC score, 3
+; magnification, 200 ×).
Table 1 Comparison of ERBB2 gene amplification and
protein expression in 69 cases of gastric cancer
IHC score IHC
n (%)
FISH
n (%)
c2 P-value
0 40(57.9%) 55(82.7%)
1
+ 16(23.3%) 3(4.3%)* 12.461 0.000
2
+ 9(13.0%) 7(10.1%)
3
+ 4(5.8%) 4(5.8%)
Total positive cases 29(42.0%) 14(20.3%)
* In comparison to FISH results from combined samples with scores of 2
+ and
3
+. IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; n,
number of positive samples.
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ERBB2 and EGFR were significantly associated with the
depth of invasion of the tumor and with lymph node
metastasis. In our search, 24.4% (10/41) and 34.1% (14/
41) of patients with lymph node metastases harbored
ERBB2 and EGFR gene amplification, respectively. (P <
0.05, Table 3).
Discussion
EGFR belongs to a family of four related receptors that
includes the EGFR (HER1), ERBB2, HER3,a n dHER4
receptors [10]. The EGFR gene is located in the short
arm of human chromosome 7 and produces a glycopro-
tein with a molecular weight of 170 kDa with high affi-
nity for the EGF ligand [11]. EGFR mediates multiple
signal transduction pathways and, thereby, connects
extracellular signaling to intracellular changes in gene
expression that modulate cellular growth and differen-
tiation. Currently, EGFR and ERBB2 are the best charac-
terized of the HER family receptors. However, little is
known regarding the expression and function of these
receptors in gastric cancer.
In recent years, interest has grown in understanding
the relationship between the biological characteristics of
gastric cancer and the association of these characteris-
tics with the clinical outcomes of the disease. Current
studies have focused on understanding the molecular
basis of gastric cancer in order to help achieve accurate
diagnoses and to better choose effective treatment
options. With the advent of novel targeted therapeutics,
these molecular characteristics may be important for
obtaining more effective therapeutic outcomes. Pre-
sently, much of the available knowledge regarding EGFR
and ERBB2 expression as well as their biological func-
tion in gastric cancer has come from countries other
than China. Research techniques for characterization of
EGFR and ERBB2 expression have included immunohis-
tochemistry (IHC), chromogenic in situ hybridization
(CISH), and FISH. Using kits approved by the United
States Federal Drug Administration for IHC (HercepT-
est™ and EGFR pharmDx™) and FISH (Path Vysion™),
we have analyzed EGFR and ERBB2 protein expression
and gene status in Chinese gastric cancer patients in
order to provide more accurate reference data for future
studies in the Chinese population.
Table 2 Comparison of EGFR gene amplification and
protein expression in 69 cases of gastric cancer
IHC score IHC
n (%)
FISH
n (%)
c2 P-value
0 33(47.8%) 49(71.0%)
1
+ 20(29.0%) 5(7.2%)* 17.016 0.000
2
+ 11(15.9%) 10(14.5%)
3
+ 5(7.3%) 5(7.2%)
Total positive cases 36(52.2%) 20(29.0%)
* In comparison to FISH results from combined samples with scores of 2
+ and
3
+. IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; n,
number of positive samples.
Table 3 Association of ERBB2 and EGFR gene amplification with clinicopathological parameters in 69 cases of gastric
cancer
Parameter n* ERBB2
Amp. *
Positive (%)
c
2 P-value EGFR
Amp. *
Positive (%)
c
2 P-value
Sex
Male 41 8(19.5) 0.316 0.574 11(26.8) 0.261 0.609
Female 28 4(14.3) 6(21.4)
Age
≥ 60 36 7(19.4) 0.221 0.638 10(27.8) 0.400 0.527
< 60 33 5(15.2) 7(21.2)
Histological type
Papillary adenocarcinoma 16 2(12.5) 3(18.8)
Tubular adenocarcinoma 14 2(14.3) 3(21.4)
Mucinous adenocarcinoma 15 3(20.0) 0.729 0.948 4(26.7) 0.714 0.950
Poorly differentiated adenocarcinoma 13 3(23.1) 4(30.8)
Signet ring cell carcinoma 11 2(18.2) 3(27.3)
Gastric cancer staging
T1/T2 25 1(4.0) 4.894 0.027 2(7.7) 5.845 0.016
T3/T4 44 11(25.0) 15(34.1)
Lymph node metastasis
Present 41 10(24.4) 6.264 0.012 14(34.1) 4.920 0.027
Absent 28 2(7.1) 3(10.7)
* n, number of samples; Amp., amplification.
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been reported in many past studies. IHC was first used
in 1986 to detect ERBB2 expression in gastric cancer
[12], which was followed by a large number of similar
reports. Reported rates of ERBB2 gene expression in
gastric cancer range were from 9% to 38%. Moreover,
the correlation between EGFR/ERBB2 expression in gas-
tric cancer and prognosis remains controversial. In the
present study, the ERBB2 protein was expressed in
42.0% (29/69) of gastric tumors, and ERBB2 gene ampli-
fication occurred in 20.3% (14/69) of tumors. Of 41
patients with lymph node metastases, ERBB2 gene
amplification was present in 24.4% (10/41) of the cases.
The EGFR protein was expressed in 52.2% (36/69) of
gastric tumors, and EGFR gene amplification occurred
in 29.0% (20/69) of tumors. Of patients with lymph
node metastases, EGFR gene amplification was present
in 34.1% (14/41) of the cases. These results suggest that
ERBB2 and EGFR gene amplification are positively asso-
ciated with ERBB2 and EGFR protein expression.
Furthermore, a higher frequency of ERBB2 and EGFR
gene amplification is present in gastric cancer patients
with lymph node metastases. EGFR and ERBB2 expres-
sion in gastric epithelial cells are indicators of malig-
nancy and may prove useful as markers for poor
prognosis in gastric cancer.
At present, pathological examination is primary
method used to assess the ERBB2 and EGFR status of
tumor cells. In particular, IHC and FISH are commonly
used in clinical settings. IHC is currently the most
widely-used method, and kits are commercially-available
for semi-quantitative detection of both ERBB2 and
EGFR. Importantly, the higher levels of ERBB2 expres-
sion are associated with improved benefit of ERBB2-tar-
geted anticancer drugs [13]. Application of IHC to
evaluate the expression of ERBB2 in tumor cells has
limitations, as the determination of staining is partially
subjective, as opposed to strictly quantitative. In con-
trast, results from the FISH are substantially less subjec-
tive than IHC, while maintaining sensitivity and
specificity. Furthermore, the quantitative nature of FISH
results can effectively reduce operator interference and
inter-laboratory variations [14]. In the present study,
FISH revealed that ERBB2 gene amplification was pre-
s e n ti n4o f4c a s e sw i t ha nI H Cs c o r eo f3
+,i n7o f9
cases with an IHC score of 2
+, and in only 3 of 16 cases
with an IHC score of 1
+. These results indicated that a
statistically significant difference in ERBB2 gene amplifi-
cation was present between the high (2
+ and 3
+)a n d
low (1
+)I H Cs c o r eg r o u p s( P < 0.05). Similar results
were observed with respect to EGFR gene amplification.
EGFR gene amplification was observed in 5 of 5 samples
with an IHC score of 3
+, in 10 of 11 samples with a
score of 2
+,a n di n5o f2 0s a m p l e sw i t has c o r eo f1
+,
which represented a significant difference between the
high (2
+ and 3
+)a n dl o w( 1
+)s c o r e s( P < 0.05). Based
on these results, the FISH assay could prove to be truly
valuable for determination of ERBB2 and EGFR expres-
sion in clinical practice.
In recent years, new developments in cancer biology
have led to the emergence of novel molecular-targeted
therapeutics. These targeted drugs selectively act on
cancer cells at the molecular, biochemical, and genetic
levels, specifically targeting abnormal cells, with minimal
effects on the function of normal cells. For example,
EGFR inhibitors have been used to block EGFR activity
and, thereby, increase the radiosensitivity of tumor cells
[15]. This phenomenon can lead to improvement of the
efficacy of radiotherapy, likely because inhibition of
EGFR signaling in tumor cells decreases cell prolifera-
tion, accelerates apoptosis, interferes with the cell cycle,
and extends the time required for DNA repair after
radiation [16]. In the present study, FISH analysis
revealed that EGFR gene amplification was present in
24.6% of the cases analyzed, and IHC showed that the
EGFR protein was expressed in 52.2% of the cases.
These results suggest that in some radiation-resistant
gastric cancer cases, targeting of EGFR for radiation sen-
sitization therapy may have important clinical value.
Co-expression of ERBB2 and EGFR m a yh a v es y n e r -
gistic effects on the progression of gastric cancer [17].
ERBB2 gene amplification was observed in20.3% (14/69)
of gastric cancer patients, including 24.4% (10/41) of the
41 patients with lymph node metastases and only 7.1%
(2/28) of patients without lymph node metastases, repre-
senting a significant difference (P <0 . 0 5 ) .EGFR gene
amplification was present in 29.0% (20/69) of gastric
cancers, including 34.1% (14/41) of patients with lymph
node metastases and 10.7% (3/28) of patients without
lymph node metastases, again representing a significant
difference (P <0 . 0 5 ) .ERBB2 and EGFR gene amplifica-
tion were also significantly related. Increased ERBB2
copy number and gene amplification were present in a
total of 57.9% (40/69) of samples. However, Both ERBB2
and EGFR gene amplification of gastric tumors were 3
cases (4.3%), but abnormalities both ERBB2 and EGFR
gene copy number were present in 36.2% of samples.
These results suggest that alterations in ERBB2 or EGFR
gene status in gastric cancer are common events that
frequently occur within the same tumor.
In summary, ERBB2 and EGFR are transmembrane
tyrosine kinases that can promote tumorigenesis and
tumor progression. Expression of ERBB2 and EGFR
appear to be closely related, and one or both proteins
are frequently overexpressed in gastric epithelial cancer
cells. Furthermore, the degree of expression is correlated
with tumor invasion, progression, and patient survival,
suggesting that these genes may represent important
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gastric cancer commonly leads to radiation resistance.
Therefore, EGFR-targeted radiosensitization treatments
may have important clinical value for treatment of gas-
tric cancer.
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